
    
      This trial is a 12 month, Phase 3, multi-center, randomized, single-masked (subject),
      controlled study designed to evaluate the utilization and safety of the MK II inserter and
      the safety of the FAI insert, in subjects with non-infectious uveitis affecting the posterior
      segment of the eye.
    
  